Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Dabrafenib and/or Trametinib in BRAF/NRAS-mutated Metastatic Melanoma
NCT02357732Phase 1Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Aug 2015
- Primary completion
- Aug 2015
01
Overview
Phase 1, open-label trial of nivolumab in melanoma, sponsored by University of Pittsburgh. Planned start Aug 2015; status: withdrawn.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02357732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357732.